TWO PEER-REVIEWED PUBLICATIONS HIGHLIGHT CLINICAL UTILITY OF PRETRM® TEST
December 23, 2016Experts Predict a Reduction of Infant Mortality by 23.5% and Annual Direct Medical Costs of More Than $500 million Through Preterm Birth Risk Testing
More »
Axial Biotherapeutics Announces the Groundbreaking Discovery of a Biological Link Between the Gut Microbiome and Parkinson’s Disease Published in Cell
December 1, 2016Caltech researchers and collaborators, led by Axial Scientific Founder Dr. Sarkis Mazmanian, show for the first time that gut bacteria promote hallmark pathology, neuroinflammation and motor dysfunction in a Parkinson’s disease mouse model
More »
Axial Biotherapeutics Launches to Treat Patients with CNS Disorders by Harnessing The Gut Microbiome
November 30, 2016Axial Licenses a New Class of CNS Biotherapeutics from the Mazmanian Laboratory at The California Institute of Technology (Caltech)
More »